Charles River Laboratories International, Inc.

New York Stock Exchange
Back to all articles
Slightly Bullish +25

Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

AI-generated analysis

- 📅 Charles River Laboratories (CRL) is scheduled to release its Q1 earnings report on May 7 for the quarter ended March 2026.

- 💸 The company is expected to report earnings of $1.96 per share, representing a year-over-year decline of 16.2%.

- 📉 Quarterly revenue is projected at $971.06 million, down 1.3% from the same quarter last year.

- 🔄 The consensus EPS estimate has been revised downward by 4.84% over the past 30 days.

- 🧠 Zacks analysis indicates a positive Earnings ESP of +0.30%, suggesting analysts are becoming more bullish recently.

- 🏆 CRL currently holds a Zacks Rank of #3 (Hold), which combined with a positive ESP points to a likely earnings beat.

- 📊 Historically, the company has beaten consensus EPS estimates in four out of the last five quarters.

- ⚠️ Past performance shows the stock beat expectations by 2.58% in the most recent reported quarter.

- 📈 Stock price movement may still vary due to other business factors regardless of whether a beat occurs.

- 🔎 Analysts are paying close attention to management's discussion on the earnings call for long-term sustainability clues.

- 👥 The Zacks model notes that negative ESP readings make it difficult to predict beats with confidence.

- 🆚 Cencora (COR) is also reporting earnings but faces a Sell rank and negative ESP of -0.80%.

- 💼 COR is expected to report EPS of $4.81 with revenue growing 7% to $80.76 billion for the quarter.

- 📅 Both companies will be featured in upcoming earnings announcements tracked by the Zacks Earnings Calendar.

- 🛠 Investors are encouraged to utilize the Zacks Earnings ESP Filter to identify potential buy or sell candidates before reports.

Bullish Signals
  • Analysts have recently become more bullish on Charles River's earnings prospects, raising the Most Accurate Estimate above the consensus level.
  • The company's Earnings ESP is positive at +0.30%, indicating a higher likelihood of beating earnings expectations based on the proprietary Zacks model.
  • Combined with a Zacks Rank of #3 (Hold), historical data suggests this combination produces an earnings beat nearly 70% of the time.
  • Charles River has a strong track record of exceeding estimates, having beaten consensus EPS in four out of the last four quarters reported.
  • The most recent quarter demonstrated a positive surprise history, with actual earnings of $2.39 per share exceeding expectations of $2.33 by +2.58%.
Risk Factors
  • Analysts have collectively revised the consensus EPS estimate for Charles River lower by 4.84% over the last 30 days, reflecting growing caution about near-term earnings.
  • The market consensus expects a year-over-year decline in earnings of -16.2%, indicating a significant negative sentiment regarding profitability growth.
  • Revenues are forecast to be $971.06 million, down 1.3% from the same quarter last year, suggesting potential revenue headwinds.
  • The company carries a Zacks Rank of #3 (Hold), which limits predictive power for an earnings beat and introduces uncertainty about stock price performance if results miss expectations.
  • A negative Earnings ESP reading is difficult to interpret as a guarantee of missing estimates, creating risk that the actual EPS will deviate from even the bullish 'Most Accurate Estimate'.
Full Analysis
Charles River Laboratories (CRL), a leading provider of medical research equipment and services, is preparing to release quarterly earnings for the period ended March 2026 on May 7. Market consensus estimates project an EPS of $1.96, representing a 16.2% year-over-year decline from the previous quarter, with total revenues expected at $971.06 million, a slight decrease of 1.3%. The Zacks Consensus Estimate for CRL has been revised down by 4.84% over the last 30 days, reflecting analysts collectively reassessing their initial forecasts. Recent trends in estimate revisions suggest that covering analysts are becoming more bullish on the company, as the Most Accurate Estimate now exceeds the Consensus Estimate by 0.30%, resulting in a positive Earnings ESP of +0.30%. According to Zacks Investment Research analysis, CRL currently holds a Zacks Rank of #3 (Hold). The research indicates that a combination of a positive Earnings ESP and a strong Zacks Rank typically predicts an earnings beat, as stocks with these attributes have produced positive surprises nearly 70% of the time. For context on CRL's historical performance, the company beat consensus estimates in all four trailing quarters, including a surprise of +2.58% in the most recently reported quarter where actual EPS of $2.39 exceeded expectations of $2.33. While an earnings beat is likely based on these metrics, investors are cautioned that stock price movements can also be influenced by management's discussion of business conditions and other factors that may disappoint investors regardless of financial results. In related industry news, competitor Cencora (COR) is also set to report earnings for the same period ended March 2026, with expectations of $4.81 per share in EPS, up 8.8% year-over-year, and revenues projected at $80.76 billion, an increase of 7%. Although Cencora has a history of beating estimates across the last four quarters, its current Earnings ESP is -0.80%, and it carries a Zacks Rank of #4 (Sell), making it difficult to predict a definitive outcome based solely on these proprietary metrics. Analysts note that while betting on companies expected to beat earnings increases the odds of success, investors should utilize tools like the Zacks Earnings Calendar and consider both earnings expectations and Zacks Ranks when forming investment decisions ahead of quarterly releases.